Cancer test kit PGX-5FU XL StripAssay®

for genotypingfor pharmacogeneticsDPD

Fluoropyrimidines are widely used for the treatment of various solid tumors. The PGX-5FU XL StripAssay® covers the four most clinically relevant variants in the dihydropyrimidine dehydrogenase (DPYD) gene with therapeutic relevance for fluoropyrimidine treatment as recommended by the European Medicines Agency in April 2020. Fluoropyrimidines (5-Fluorouracil, Capecitabine and Tegafur) are frequently used in cancer therapy. However, some patients develop severe treatment-related toxicity. A part of fluoropyrimidine-related toxicity arises due to impaired activity of the key metabolic enzyme dihydropyrimidine dehydrogenase (DPD) caused by genetic variants in the DPYD gene. CPIC Guidelines recommend DPYD genotype-guided fluoropyrimidine dosing to increase patient safety.